These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 18301416)

  • 21. Abacavir hypersensitivity reaction predicted by genetic test.
    AIDS Treat News; 2004 Mar; (399):6. PubMed ID: 15199868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study.
    Rauch A; Nolan D; Martin A; McKinnon E; Almeida C; Mallal S
    Clin Infect Dis; 2006 Jul; 43(1):99-102. PubMed ID: 16758424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genotypic Approaches to Therapy in Children (GATC): using information technology to improve drug safety.
    Wong E; Carleton BC; Wright DF; Smith MA; Verbeek L; Hildebrand CA; Stannard P; Vaillancourt R; Elliot-Miller P; Ross CJ; Hayden MR
    Stud Health Technol Inform; 2009; 143():209-14. PubMed ID: 19380938
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome.
    Martin AM; Krueger R; Almeida CA; Nolan D; Phillips E; Mallal S
    Pharmacogenet Genomics; 2006 May; 16(5):353-7. PubMed ID: 16609367
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacogenetic contribution to individualized treatment. Severe adverse effects can be avoided].
    Eliasson E
    Lakartidningen; 2008 May 28-Jun 3; 105(22):1644-5. PubMed ID: 18590003
    [No Abstract]   [Full Text] [Related]  

  • 26. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience.
    Waters LJ; Mandalia S; Gazzard B; Nelson M
    AIDS; 2007 Nov; 21(18):2533-4. PubMed ID: 18025891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential genome-wide association studies for monitoring adverse events in the clinical evaluation of new drugs.
    Kelly P; Stallard N; Zhou Y; Whitehead J; Bowman C
    Stat Med; 2006 Sep; 25(18):3081-92. PubMed ID: 16397864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [HLA-B*5701 and abacavir hypersensitivity reaction].
    Servonnet A; Leclercq E; Delacour H; Ceppa F
    Pathol Biol (Paris); 2010 Dec; 58(6):e95-100. PubMed ID: 19243901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The contribution of pharmacogenetics to pharmacovigilance.
    Bondon-Guitton E; Despas F; Becquemont L
    Therapie; 2016 Apr; 71(2):223-8. PubMed ID: 27080842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant.
    Martin AM; Nolan D; Gaudieri S; Almeida CA; Nolan R; James I; Carvalho F; Phillips E; Christiansen FT; Purcell AW; McCluskey J; Mallal S
    Proc Natl Acad Sci U S A; 2004 Mar; 101(12):4180-5. PubMed ID: 15024131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Should HLA-B*5701 screening be performed in every ethnic group before starting abacavir?
    Park WB; Choe PG; Song KH; Lee S; Jang HC; Jeon JH; Park SW; Park MH; Oh MD; Choe KW
    Clin Infect Dis; 2009 Feb; 48(3):365-7. PubMed ID: 19115972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genome-based pharmacogenetics and the pharmaceutical industry.
    Roses AD
    Nat Rev Drug Discov; 2002 Jul; 1(7):541-9. PubMed ID: 12120260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful implementation of a national HLA-B*5701 genetic testing service in Canada.
    Lalonde RG; Thomas R; Rachlis A; Gill MJ; Roger M; Angel JB; Smith G; Higgins N; Trottier B
    Tissue Antigens; 2010 Jan; 75(1):12-8. PubMed ID: 19843279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
    Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR
    Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan.
    Sun HY; Hung CC; Lin PH; Chang SF; Yang CY; Chang SY; Chang SC
    J Antimicrob Chemother; 2007 Sep; 60(3):599-604. PubMed ID: 17631508
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies.
    Tonk ECM; Gurwitz D; Maitland-van der Zee AH; Janssens ACJW
    Pharmacogenomics J; 2017 Jul; 17(4):386-392. PubMed ID: 27168098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study.
    Rauch A; Nolan D; Thurnheer C; Fux CA; Cavassini M; Chave JP; Opravil M; Phillips E; Mallal S; Furrer H;
    Antivir Ther; 2008; 13(8):1019-28. PubMed ID: 19195327
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Correlation, in previously treated HIV-1 positive patients, between hypersensitivity reaction to abacavir and the presence of the HLA-B*5701 allele].
    Pérez Prior N; Rocher Milla A; Soler Company E; Flores Cid J; Sarria Chust B
    Farm Hosp; 2009; 33(3):155-60. PubMed ID: 19712599
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenomic biomarkers for prediction of severe adverse drug reactions.
    Ingelman-Sundberg M
    N Engl J Med; 2008 Feb; 358(6):637-9. PubMed ID: 18256400
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacogenomics of antimicrobial agents.
    Aung AK; Haas DW; Hulgan T; Phillips EJ
    Pharmacogenomics; 2014; 15(15):1903-30. PubMed ID: 25495412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.